Sotabase

Career

· Chief Revenue Scientist, Varicent2020–2024
· Research Scientist, Massachusetts Institute of Technology (MIT)2019–
· Chief Economist and Chief Analytics Officer, IBM2010–2019
· Head of Emerging Business Opportunity program, IBM1999–2006
· Principal Economic Consultant, Abt Associates1996–1999
· Vice President, Strategy, Cahners Business Information1991–1996
· Ph.D. in Economics, Tufts University1976–1980
· M.A. in Economics, Tufts University1974–1976
· B.Sc. in Mathematics, University of Massachusetts Lowell1970–1974

Publications (130)

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network · 2019
351
cited
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
The Journal of the National Comprehensive Cancer Network · 2021
252
cited
Melanoma, version 2.2016 clinical practice guidelines in oncology
2016
171
cited
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients
BMC Cancer · 2018
128
cited
Principles of management of basal and squamous cell carcinoma of the skin
Cancer · 1995
118
cited
Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines
2013
117
cited
Lymphedema Therapy Reduces the Volume of Edema and Pain in Patients with Breast Cancer
Annals of Surgical Oncology · 2007
112
cited
NCCN Guidelines Insights: Melanoma, Version 3.2016.
The Journal of the National Comprehensive Cancer Network · 2016
100
cited
Colon cancer with metastasis to the ovary at time of initial diagnosis.
Gynecologic Oncology · 1997
96
cited
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
The Journal of the National Comprehensive Cancer Network · 2016
83
cited
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
Future Oncology · 2019
78
cited
Melanoma, version 2.2013: featured updates to the NCCN guidelines.
The Journal of the National Comprehensive Cancer Network · 2013
68
cited
The feasibility of adjuvant interferon α‐2b in children with high‐risk melanoma
2005
58
cited
Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)
Cancer · 2021
50
cited
Long-term results of breast conservation therapy for breast cancer.
Annals of Surgery · 1996
45
cited
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction
JCO Precision Oncology · 2021
39
cited
Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients
2018
37
cited
Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers
iScience · 2019
35
cited
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.
The Journal of the National Comprehensive Cancer Network · 2020
32
cited
The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
Cancer · 2005
27
cited
Sotabase
Martin Fleming | Researcher Profile | Sotabase | Sotabase